IMRX

SEC filing IMRX Reports 17.3 Month Median OS, 36% ORR, 82% DCR in Phase 2a Atebimetinib Trial for Pancreatic Cancer

1d ago

News Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket

14d ago

News Immuneering GAAP EPS of -$0.21 beats by $0.04

18d ago

SEC filing IMRX Reports 64% 12M OS in Pancreatic Cancer, $217M Cash Runway to 2029, MAPKeeper 301 Phase 3 2026

88d ago

Insider trade Purchase by Peter Feinberg

104d ago

Insider trade Purchase by Brett Matthew Hall

104d ago

Insider trade Purchase by Harold Eugene Brakewood

104d ago

News Analysts Reiterate Magnite Inc’s (MGNI) Huge Upside

126d ago

News Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus

145d ago

News Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer

145d ago

News Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

145d ago

Scanner Unusual volume (z=11.3)

160d ago

Scanner Unusual volume (z=11.5)

162d ago

Scanner Unusual volume (z=11.5)

163d ago

Scanner Unusual volume (z=11.5)

164d ago